Czynnik X (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Czynnik X" in Polish language version.

refsWebsite

Global rank Polish rank

7doi.org

2^nd place

6^th place

4nih.gov

4^th place

7^th place

3worldcat.org

5^th place

2^nd place

doi.org

dx.doi.org

BettyB. Landesman BettyB., PubMed Central, „Reference Reviews”, 19 (3), 2005, s. 37–38, DOI: 10.1108/09504120510587797, ISSN 0950-4125 [dostęp 2020-11-21] .
Eric P.E.P. Skaar Eric P.E.P., JillJ. Pulley JillJ., ., PheWAS uncovers a pathological role of coagulation Factor X during Acinetobacter, „Infection and Immunity”, 87 (5), 2019, IAI.00031–19, DOI: 10.1128/IAI.00031-19, ISSN 0019-9567, PMID: 30782860, PMCID: PMC6479028 .
T.T. Jakab T.T. i inni, Poster Session I: Degradation of Factor VIII-Related Protein in Factor VIII Concentrates, [w:] XIIth Congress of The World Federation of Hemophilia, „Thrombosis and Haemostasis”, 38 (1 (5)), Schattauer GmbH, 1977, DOI: 10.1055/s-0039-1682495 [dostęp 2020-11-21] .
FDA approves Factor X therapy for rare bleeding condition, „The Pharmaceutical Journal”, 2015, DOI: 10.1211/pj.2015.20069602, ISSN 2053-6186 [dostęp 2020-11-21] .
MaureaneM. Hoffman MaureaneM., Dougald M.D.M. Monroe Dougald M.D.M., Coagulation 2006: a modern view of hemostasis, „Hematology/Oncology Clinics of North America”, 21 (1), s. 1–11, DOI: 10.1016/j.hoc.2006.11.004, PMID: 17258114 .
A.G.A.G. Turpie A.G.A.G., Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases, „Arteriosclerosis, Thrombosis, and Vascular Biology”, 27 (6), s. 1238–47, DOI: 10.1161/ATVBAHA.107.139402, PMID: 17379841, CiteSeerX 10.1.1.536.872. .
BrozeB. GJ BrozeB. i inni, The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action, „Blood”, 71 (2), s. 335–43, DOI: 10.1182/blood.V71.2.335.335, PMID: 3422166 .

nih.gov

ncbi.nlm.nih.gov

Eric P.E.P. Skaar Eric P.E.P., JillJ. Pulley JillJ., ., PheWAS uncovers a pathological role of coagulation Factor X during Acinetobacter, „Infection and Immunity”, 87 (5), 2019, IAI.00031–19, DOI: 10.1128/IAI.00031-19, ISSN 0019-9567, PMID: 30782860, PMCID: PMC6479028 .
MaureaneM. Hoffman MaureaneM., Dougald M.D.M. Monroe Dougald M.D.M., Coagulation 2006: a modern view of hemostasis, „Hematology/Oncology Clinics of North America”, 21 (1), s. 1–11, DOI: 10.1016/j.hoc.2006.11.004, PMID: 17258114 .
A.G.A.G. Turpie A.G.A.G., Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases, „Arteriosclerosis, Thrombosis, and Vascular Biology”, 27 (6), s. 1238–47, DOI: 10.1161/ATVBAHA.107.139402, PMID: 17379841, CiteSeerX 10.1.1.536.872. .
BrozeB. GJ BrozeB. i inni, The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action, „Blood”, 71 (2), s. 335–43, DOI: 10.1182/blood.V71.2.335.335, PMID: 3422166 .

worldcat.org

BettyB. Landesman BettyB., PubMed Central, „Reference Reviews”, 19 (3), 2005, s. 37–38, DOI: 10.1108/09504120510587797, ISSN 0950-4125 [dostęp 2020-11-21] .
Eric P.E.P. Skaar Eric P.E.P., JillJ. Pulley JillJ., ., PheWAS uncovers a pathological role of coagulation Factor X during Acinetobacter, „Infection and Immunity”, 87 (5), 2019, IAI.00031–19, DOI: 10.1128/IAI.00031-19, ISSN 0019-9567, PMID: 30782860, PMCID: PMC6479028 .
FDA approves Factor X therapy for rare bleeding condition, „The Pharmaceutical Journal”, 2015, DOI: 10.1211/pj.2015.20069602, ISSN 2053-6186 [dostęp 2020-11-21] .